Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin

被引:42
作者
Djalilian, Ali R. [1 ]
Nagineni, Chandrasekharam N. [1 ]
Mahesh, Sankanaranayana P. [1 ]
Smith, Janine A. [1 ]
Nussenblatt, Robert B. [1 ]
Hooks, John J. [1 ]
机构
[1] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA
关键词
cornea; inflammation; cytokines; chemokines; dexamethasone; cyclosporin;
D O I
10.1097/01.ico.0000208815.02120.90
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the modulatory effects of anti-inflammatory agents, dexamethasone (Dex) and cyclosporin A (CsA), on the production of cytokines and chemokines by human corneal cells in vitro following stimulation by the pro-inflammatory cytokine after interleukin 1 beta (IL-1 beta). Methods: A human corneal epithelial (HCE) cell line and human corneal fibroblasts (HCFs) were stimulated in culture with IL-10 and treated with Dex or CsA. The gene expression for selected cytokines and chemokines was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). The secretion of cytokines and chemokines was measured by enzyme-linked immunosorbent assay. Results: IL-1 beta enhanced the mRNA and/or protein levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-8, and monocyte chemotactic protein (MCP)-1 in HCE and IL-6, IL-8, MCP-3, and regulated on T-cell activation expressed secreted (RANTES) in HCFs. Treatment with CsA did not inhibit cytokine production in either HCE or HCFs. In contrast, Dex treatment inhibited the IL-1 beta-induced production of GM-CSF, IL-6, IL-8, MCP-3, and RANTES, but not MCP-1. Conclusion: These results show that Dex, but not CsA, has direct immunosuppressive effects on the resident corneal cells, HCE and HCFs. This suggests that the clinically observed immunosuppressive effects of topical CsA are mediated primarily through the immune cells.
引用
收藏
页码:709 / 714
页数:6
相关论文
共 33 条
[1]   Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs [J].
Acheampong, AA ;
Shackleton, M ;
Tang-Liu, DDS ;
Ding, SL ;
Stern, ME ;
Decker, R .
CURRENT EYE RESEARCH, 1999, 18 (02) :91-103
[2]  
ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614
[3]   IMMUNOSUPPRESSIVE AGENTS IN PENETRATING KERATOPLASTY [J].
BARRAQUER, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1985, 100 (01) :61-64
[4]  
Baudouin C, 2002, ADV EXP MED BIOL, V506, P761
[5]  
CUBITT CL, 1993, INVEST OPHTH VIS SCI, V34, P3199
[6]  
CUBITT CL, 1994, J IMMUNOL, V153, P232
[7]  
CUBITT CL, 1995, INVEST OPHTH VIS SCI, V36, P330
[8]   Topical interleukin 1 receptor antagonist promotes corneal transplant survival [J].
Dana, MR ;
Yamada, J ;
Streilein, JW .
TRANSPLANTATION, 1997, 63 (10) :1501-1507
[9]   Twenty-five-year panorama of corneal immunology - Emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection [J].
Dana, MR ;
Qian, Y ;
Hamrah, P .
CORNEA, 2000, 19 (05) :625-643
[10]   Interleukin-1/toll receptor family members: Receptor structure and signal transduction pathways [J].
Daun, JM ;
Fenton, MJ .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (10) :843-855